医学
恩扎鲁胺
前列腺癌
临床试验
肿瘤科
内科学
疾病
癌症
雄激素受体
作者
Valeria Emma Palmieri,Giandomenico Roviello,Alberto D’Angelo,Chiara Casadei,Ugo De Giorgi,Roberta Giorgione
标识
DOI:10.1080/17512433.2021.1901580
摘要
Introduction: Important changes in the treatment of prostate cancer have taken place in recent years. Non-metastatic castration-resistant prostate cancer (nmCRPC) has been clinically delineated. In this setting, three drugs have been approved in high-risk disease: apalutamide, enzalutamide and darolutamide.Areas covered:This manuscript aims to profile darolutamide, its clinical development, pharmacologic properties, efficacy and safety. We presented the results of published clinical studies, but we also investigated ongoing ones.Expert opinion: An indirect comparison with the other two aforementioned drugs emerged. While the clinical efficacy is comparable, the toxicity profile is different for darolutamide, resulting in greater tolerance. We must wait for the results of the trials that study darolutamide in hormone-sensitive disease, both in the metastatic phase and in the localized phase. Clinical experience will also be important to determine ever more personalized treatments for patients.
科研通智能强力驱动
Strongly Powered by AbleSci AI